Core Viewpoint - DarioHealth Corp. will release its financial results for the first quarter of 2025 on May 14, 2025, and will host a conference call to discuss these results [1][2]. Group 1: Conference Call Details - The conference call is scheduled for May 14, 2025, at 8:30 a.m. Eastern Time [3]. - Participants can join via a domestic dial-in number (1-800-717-1738) or an international number (1-646-307-1865) [3]. - A replay of the call will be available approximately two hours after the event until May 28, 2025 [3]. Group 2: Company Overview - DarioHealth Corp. is a leader in the digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [4]. - The platform provides personalized interventions for conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health [4]. - DarioHealth's approach aims to empower users to make sustainable lifestyle changes, enhancing user satisfaction and retention [5]. Group 3: Market Reach - DarioHealth offers its solutions globally to health plans, self-insured employers, care providers, and consumers [6].

Rocket Doctor named Clinical Innovator of the Year at the Innovators Challenge during NEXUS 2025 in New Orleans. Award recognizes Rocket Doctor's physician-led virtual care model, designed to empower doctors and expand access to care. Platform enables independent physicians to launch and manage their own virtual or hybrid practices with built-in support and AI tools. Selected as winner following a live pitch session judged by top healthcare leaders and digital health experts. This recognition comes during a ...

Group 1 - Dawn Health has secured EUR 11.5 million in funding from existing investors to scale its platform and product suite for next-generation pharmaceutical digital health solutions [1] - The company has developed a platform tailored for the pharmaceutical industry, which has been adopted by major players like Merck and Novartis [2] - The Dawn Platform enhances patient care and outcomes through advanced capabilities in AI, data analytics, and clinical integrations, supporting therapy companions and disease management programs [3] Group 2 - The CEO of Dawn Health emphasized the ambition to lead in digital health and improve patient lives globally, with the new funding aimed at expanding market reach [4] - Since a major investment in December 2021, Dawn Health has significantly increased its revenue and workforce, now employing over 100 people [5] - Dawn Health specializes in Software as a Medical Device (SaMD) and Digital Therapeutics (DTx), focusing on chronic conditions and patient-centric solutions [6]

Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors [4] - The company has two subsidiaries: Lucid Diagnostics, which focuses on cancer prevention diagnostics, and Veris Health, which enhances personalized cancer care through remote patient monitoring [4] Upcoming Conference Call - PAVmed will host a business update conference call and webcast on May 15, 2025, at 8:30 AM ET [1] - The call will feature Lishan Aklog, M.D., providing an overview of the company's operations and growth strategy, and Dennis McGrath discussing the first quarter 2025 financial results [1] Access Information - The webcast will be available on the investor relations section of the company's website [2] - U.S.-based callers can join the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2] Replay Availability - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]

Core Viewpoint - Octopus Titan VCT plc reported a disappointing total return of -14.1% for the year ending December 31, 2024, with net assets decreasing to £831 million, primarily due to company-specific performance issues and challenging market conditions [3][4][27]. Financial Summary - Net assets decreased from £993.74 million in 2023 to £831.358 million in 2024 [2]. - Loss after tax for the year was £147.649 million, slightly improved from £149.499 million in the previous year [2]. - NAV per share fell from 62.4p in 2023 to 50.5p in 2024, reflecting a decrease of 8.8p per share [2][3]. - Total value per share decreased from 164.4p in 2023 to 155.6p in 2024 [2][7]. - Total return per share was -8.8p, translating to a total return percentage of -14.1% for the year [2][7]. - Dividends paid in 2024 totaled 3.1p, down from 5.0p in 2023, resulting in a dividend yield of 5.0% [2][13]. Performance Analysis - The decline in NAV was attributed to underperformance of portfolio companies, particularly Pelago, Many Pets, and Big Health, which collectively accounted for about one-third of the total NAV decline [4][48][49]. - The five-year tax-free annual compound return for shareholders is now -3.5%, and since the high watermark at December 31, 2021, the total return per share has decreased by 39.8% [5][27]. - The company utilized £137 million of cash resources during the year, with £30 million allocated to new and follow-on investments [6]. Strategic Review - A strategic review was initiated in September 2024 to address performance challenges and develop a plan for future sustainability and improved performance [10][30]. - The review includes an analysis of historical investment performance, sustainability, future investment strategy, and team structure [10][34]. - The Board is considering feedback from a shareholder survey indicating significant dissatisfaction with past performance and capital growth opportunities [10][71]. Portfolio Management - The portfolio consists of over 135 companies, with 42% not expecting further funding needs, increasing to 67% when including those with more than 12 months' cash runway [29]. - In 2024, Titan completed 8 new investments and 14 follow-on investments totaling £30 million [68]. - The company returned £29 million in cash proceeds from exits during the year, which was below the level achieved in 2023 [28][56]. Governance and Management Changes - Erin Platts was appointed as the new CEO of Octopus Ventures in January 2025, bringing extensive experience from her previous role at HSBC Innovation Banking UK [41][42]. - The Board has acknowledged the turnover in the Octopus Ventures team and is assessing the team structure and culture as part of the ongoing strategic review [23][30].

Company Leadership Transition - DarioHealth Corp. announced the retirement of Chief Financial Officer Zvi Ben-David, effective May 15, 2025 [1][2] - Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary, set to assume the role upon Mr. Ben-David's retirement [2][3] - Mr. Ben-David will assist the company in an advisory capacity until the end of June 2025 to ensure a smooth transition [2] New CFO's Background - Chen Franco-Yehuda brings extensive financial leadership experience, particularly in corporate finance, capital markets, and strategic growth initiatives [3] - She previously served as CFO at Pluri Inc., where she led financial strategy and secured substantial capital through various fundraising rounds [4] - Franco-Yehuda has a background as an Audit/Assurance Manager at PwC and is a licensed CPA in Israel [5] Company Growth and Strategy - Under Mr. Ben-David's leadership, DarioHealth transformed from a single-condition solution provider to a comprehensive multi-condition digital health platform [6] - The company has expanded its offerings across various health conditions, including diabetes, hypertension, mental health, weight management, and musculoskeletal care [6] - DarioHealth aims to leverage Franco-Yehuda's expertise to continue driving innovation and growth in the digital health sector [6][7]

Core Viewpoint - iRhythm Technologies, Inc. will release its financial results for Q1 2025 on May 1, 2025, followed by a conference call to discuss the results [1]. Company Overview - iRhythm Technologies is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3]. - The company utilizes wearable biosensors and cloud-based data analytics combined with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3]. - iRhythm's vision emphasizes improving patient care through better data, insights, and health outcomes [3]. Conference Call Details - The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day as the financial results release [1]. - Interested parties can access a live and archived webcast of the conference call on the company's investor website [2].

Core Insights - DarioHealth Corp. has formed a strategic partnership with a leading benefit administrator to provide a comprehensive cardiometabolic solution, which includes a GLP-1 support program and an AI-driven digital health suite, contributing to recurring revenues since January 2025 [1][2][4] - The partnership aims to address rising healthcare costs associated with metabolic conditions, particularly focusing on the demand for effective GLP-1 medication support [2][4] - Dario's approach includes a complete lifecycle management solution that supports members from medication initiation to long-term weight maintenance, addressing the challenge of medication discontinuation [3][4] Company Overview - DarioHealth Corp. is a leader in the digital health market, offering a user-centric platform for managing chronic conditions through personalized interventions driven by data analytics [5][6] - The company's platform aims to disrupt traditional episodic healthcare by providing continuous and customized care, promoting sustainable behavior change [6][7] Market Potential - The GLP-1 market is projected to grow to $100 billion by 2030, while the broader cardiometabolic disease market is expected to exceed $1.2 trillion by 2033 [3][4] - Research indicates that without proper behavioral support, 50-75% of patients discontinue GLP-1 medications within one year, highlighting the need for effective management solutions [3]

Core Insights - Transcarent has completed the acquisition of Accolade for approximately $621 million, enhancing its digital health offerings [1][2] - Accolade shareholders received $7.03 per share in cash, and the company's stock will no longer be traded on Nasdaq [2] - Transcarent aims to create a new health and care experience by integrating Accolade's capabilities, emphasizing the benefits of their combined resources [3] Company Overview - Transcarent provides at-risk pricing models to self-insured employers, facilitating quick access to care and benefits navigation for employees [3] - As of May, Transcarent has raised around $450 million, achieving a valuation of $2.2 billion [3] - The company was recognized on CNBC's Disruptor 50 list last year, highlighting its innovative approach in the digital health sector [3]

Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition managementNEW YORK, April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions. The signed agreement is already live a ...